Ann: Neuren to present at MST Access investor conference, page-14

Little T,

I see from the clinical trials site that 180 were planned to be enrolled in Lavender, 180 in Lilac 1, and 153 in Lilac 2.

At first glance this suggests a drop out of 27 patients, BUT
1) It's highly unlikely that the last few patients now enrolling in Lavender would ever make it through to Lilac 2, because the drug will either be approved or not before they finish Lilac 1, and
2) Some of the girls dropping out of Lavender/Lilac 1 may have done so for reasons other than side effects i.e. Covid etc

So if 153 were actually to enroll, I would see that as an outstanding number, suggesting very few drop outs caused by side effects.

But perhaps I am reading that info incorrectly??